NGS provides comprehensive profiling and analytic capabilities that assist in medical decision making. It is a scalable technology and requires minimum sample input.
Vela Diagnostics provides a Next-Generation Sequencing (NGS) solution* that is simple, fast, and affordable -- putting the power of NGS technology in the reach of labs of all sizes. The solution is easy-to-use, from automated template preparation and library construction, to sequencing, data analysis and reporting.
The automated solution reduces sample-to-sample variability, minimizes risk of rerun due to user error/inconsistency and help produce more accurate results. With parallel preparation and subsequent analysis of up to 16 sample barcodes, sequencing pipelines are optimized.
The Vela Diagnostics NGS platform uses semi-conductor based sequencing technologies to translate chemical signals into meaningful information. Ideal for sequencing targeted regions, the integrated Next-Generation Sequencing (NGS) solution from Vela Diagnostics detects single nucleotide variants as well as insertions and deletions.
Several Vela Diagnostics’ NGS assays are being developed to identify sequence variants of demonstrated importance, including gene mutations relevant to oncology and viral genotypes, using a variety of sample materials.
Vela Diagnostics launched its integrated Next-Generation Sequencing (NGS) portfolio for the detection of gene mutations with the Sentosa SQ Melanoma Panel. It marked the first NGS-based oncology panel available for diagnostic use.
Automated data analysis and reporting with Sentosa Reporter turns sophisticated data into concise, clear reports. Open-channel capability is also available, offering users the opportunity to customize and apply user-defined protocols.